Desiccated Thyroid (Armour Thyroid) Should Not Be Used for Hypothyroidism Treatment
The American Association of Clinical Endocrinologists and American Thyroid Association explicitly recommend against using desiccated thyroid hormone for the treatment of hypothyroidism (Grade D recommendation). 1 There is no evidence-based conversion protocol because conversion from levothyroxine 250 µg to Armour Thyroid is not a recommended therapeutic approach.
Why This Recommendation Exists
The guideline position is unequivocal: "There is no evidence to support using desiccated thyroid hormone in preference to L-thyroxine monotherapy in the treatment of hypothyroidism and therefore desiccated thyroid hormone should not be used for the treatment of hypothyroidism." 1 This was a unanimous expert opinion based on:
- Variable hormone content: The ratio of T4 to T3 in desiccated thyroid preparations varies by brand and whether it's porcine or bovine origin 1
- Non-physiologic T3:T4 ratio: Armour Thyroid contains approximately a 4:1 ratio by weight of T4 to T3 1, which differs substantially from the human thyroid's natural production
- Lack of systematic study: Desiccated thyroid has not been systematically studied for safety and efficacy 1
The Evidence Landscape
While recent research shows some patients report subjective preference for DTE:
- A 2013 crossover study found 48.6% of patients preferred DTE over levothyroxine, with modest weight loss (3 lbs) 2
- A 2021 case series showed improved quality of life scores in levothyroxine-unresponsive patients switched to DTE 3
- A 2024 systematic review concluded that most DTE studies are hampered by inferior design, with two RCTs showing no difference in quality of life or symptom scores 4
However, these studies do not override the guideline recommendation, particularly given concerns about:
- Significantly higher T3 levels with DTE (mean difference: 50.90 ng/dL higher) 5
- Significantly lower T4 levels 5
- Potential cardiovascular risks from supraphysiologic T3 levels
- Lack of long-term safety data 4
If Conversion Is Absolutely Necessary Despite Guidelines
The FDA label for Armour Thyroid provides dosing information but no direct conversion from levothyroxine 6:
- Typical maintenance doses: 60-120 mg daily of Armour Thyroid
- Starting approach: Begin with 30 mg daily, with increments of 15 mg every 2-3 weeks
- For patients with cardiovascular concerns: Start with 15 mg daily
For a patient on levothyroxine 250 µg (a high dose suggesting athyreotic state or malabsorption), a rough approximation would be:
- 100 µg levothyroxine ≈ 60-65 mg Armour Thyroid (based on historical equivalency tables)
- Therefore, 250 µg levothyroxine ≈ approximately 150-160 mg Armour Thyroid
Critical monitoring requirements if this conversion proceeds:
- Check TSH and free T4 in 4-8 weeks 1
- Monitor heart rate and cardiovascular symptoms closely 6
- Watch for signs of overtreatment (atrial fibrillation risk, bone loss in postmenopausal women) 1
- Expect lower free T4 and higher T3 levels 5
The Better Approach
Before considering DTE, address why the patient requires 250 µg levothyroxine:
- Compliance issues: Most common cause of high-dose requirements 1
- Malabsorption: Medications (PPIs, calcium, iron), celiac disease, atrophic gastritis
- Timing of administration: Should be taken 30-60 minutes before breakfast or 4 hours after last meal 1
- Drug interactions: Review Table 10 in guidelines for interfering substances 1
- Consider liquid or softgel formulations if absorption is suspected 7
The evidence strongly supports continuing levothyroxine monotherapy and optimizing its delivery rather than switching to desiccated thyroid.